Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Horizon Therapeutics plc

https://www.horizontherapeutics.com

Latest From Horizon Therapeutics plc

TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.

Clinical Trials Business Strategies

Acer’s ‘Misunderstood Drugs’ Strategy Faces Regulatory Hurdles

Acer repurposes drugs with available data (like a 40-year-old European antihypertensive) into rare disease treatments (like Edsivo for vascular Ehlers-Danlos syndrome), but approval remains elusive, with a CRL for ACER-001 just as Edsivo is poised to enter a new clinical trial, armed with a new breakthrough designation. The Pink Sheet delves into regulatory history and strategy with CEO Chris Schelling.

Rare Diseases Complete Response Letters

Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation

The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line

Clinical Trials Business Strategies

Acer’s ‘Misunderstood Drugs’ Strategy Faces Regulatory Hurdles

Acer repurposes drugs with available data (like a 40-year-old European antihypertensive) into rare disease treatments (like Edsivo for vascular Ehlers-Danlos syndrome), but approval remains elusive, with a CRL for ACER-001 just as Edsivo is poised to enter a new clinical trial, armed with a new breakthrough designation. The Pink Sheet delves into regulatory history and strategy with CEO Chris Schelling.

Rare Diseases Complete Response Letters
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Bio-Technology General Corporation
    • Crealta Holdings LLC
    • Crealta Pharmaceuticals
    • Curzion Pharmaceuticals, Inc.
    • Encode Pharmaceuticals, Inc.
    • Horizon Pharma plc
    • Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
    • Nitec Pharma AG
    • Raptor Pharmaceutical Corp.
    • River Vision Development Corp.
    • Savient Pharmaceuticals, Inc. (SVNT)
    • TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
    • Vidara Therapeutics Inc
    • Viela Bio, Inc.
UsernamePublicRestriction

Register